Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer.
Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H, Behrens T, Chandra A, Goebell PJ, Palou J, Sanchez-Carbayo M, Schmitz-Dräger BJ. Kamat AM, et al. Among authors: todenhofer t. Urol Oncol. 2014 Oct;32(7):1069-77. doi: 10.1016/j.urolonc.2014.06.017. Epub 2014 Oct 11. Urol Oncol. 2014. PMID: 25306288 Review.
Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III.
Reike MJ, Ingersoll MA, Müller DC, Zuiverloon TCM, Strandgaard T, Kamat AM, Williams SB, Seiler R, Todenhöfer T, Dyrskjøt L, Nawroth R, Goebell P, Schmitz-Dräger B, Sfakianos JP, Meeks J, Horowitz A, Black PC. Reike MJ, et al. Among authors: todenhofer t. Urol Oncol. 2023 May;41(5):211-218. doi: 10.1016/j.urolonc.2022.09.012. Epub 2022 Oct 18. Urol Oncol. 2023. PMID: 36266219 Review.
Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines.
Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Todenhöfer T, Vlahou A, Grossman HB, Schoenberg MP, Sanchez-Carbayo M, Brünn LA, van Rhijn BW, Goebell PJ, Kamat AM, Roupret M, Shariat SF, Kiemeney LA. Schmitz-Dräger BJ, et al. Among authors: todenhofer t. Urol Oncol. 2016 Oct;34(10):437-51. doi: 10.1016/j.urolonc.2016.05.030. Epub 2016 Sep 15. Urol Oncol. 2016. PMID: 27641313 Review.
A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow.
Rossnagl S, Ghura H, Groth C, Altrock E, Jakob F, Schott S, Wimberger P, Link T, Kuhlmann JD, Stenzl A, Hennenlotter J, Todenhöfer T, Rojewski M, Bieback K, Nakchbandi IA. Rossnagl S, et al. Among authors: todenhofer t. Cancer Res. 2018 Jan 1;78(1):129-142. doi: 10.1158/0008-5472.CAN-16-3507. Epub 2017 Oct 24. Cancer Res. 2018. PMID: 29066511
An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer.
Zekri L, Vogt F, Osburg L, Müller S, Kauer J, Manz T, Pflügler M, Maurer A, Heitmann JS, Hagelstein I, Märklin M, Hörner S, Todenhöfer T, Calaminus C, Stenzl A, Pichler B, la Fougère C, Schneider MA, Rammensee HG, Zender L, Sipos B, Salih HR, Jung G. Zekri L, et al. Among authors: todenhofer t. EMBO Mol Med. 2021 Feb 5;13(2):e11902. doi: 10.15252/emmm.201911902. Epub 2020 Dec 29. EMBO Mol Med. 2021. PMID: 33372710 Free PMC article.
Is there an anti-androgen withdrawal syndrome for enzalutamide?
von Klot CA, Kramer MW, Böker A, Herrmann TR, Peters I, Kuczyk MA, Ligges U, Gschwend JE, Retz M, Schmid SC, Stenzl A, Schwentner C, Todenhöfer T, Stöckle M, Ohlmann CH, Azone I, Mager R, Bartsch G, Haferkamp A, Heidenreich A, Piper C, Merseburger AS. von Klot CA, et al. Among authors: todenhofer t. World J Urol. 2014 Oct;32(5):1171-6. doi: 10.1007/s00345-014-1288-3. Epub 2014 Apr 2. World J Urol. 2014. PMID: 24691670
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
Necchi A, Ramlau R, Falcón González A, Chaudhry A, Todenhöfer T, Tahbaz R, Fontana E, Giannatempo P, Deville JL, Pouessel D, Yoon S, Powles T, Bernat M, Häckl M, Marszewska M, McKernan P, Saulay M, Scaleia F, Engelhardt M, Loriot Y, Siefker-Radtke A, De Santis M. Necchi A, et al. Among authors: todenhofer t. JNCI Cancer Spectr. 2024 Apr 16:pkae030. doi: 10.1093/jncics/pkae030. Online ahead of print. JNCI Cancer Spectr. 2024. PMID: 38627238
Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer.
Benderska-Söder N, Ecke T, Kleinlein L, Roghmann F, Bismarck E, van Rhijn BWG, Stenzl A, Witjes JA, Todenhöfer T, Hakenberg OW, Grimm MO, Goebell PJ, Burger M, Jensen JB, Schmitz-Dräger BJ. Benderska-Söder N, et al. Among authors: todenhofer t. Urol Oncol. 2024 Feb 24:S1078-1439(24)00041-3. doi: 10.1016/j.urolonc.2024.01.025. Online ahead of print. Urol Oncol. 2024. PMID: 38403529 Review.
189 results